Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 901–1,000 of 1,000
Varghese, C., Liu, V. Y., Immanuel, T., Chien, N., Green, T. N., Chan, G. T. C., Theakston, E., & Kalev‐Zylinska, M. L. (2021) · Hematology · doi:10.1080/16078454.2021.1882146 · Cited by 6
“remission and long-term survival in >90% patients [5].”
BackgroundYanada, M., Ota, S., Mukae, J., Nara, M., Kako, S., Nishikawa, A., Uchida, N., Sawa, M., Nakano, N., Onizuka, M., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01501-9 · Cited by 6
Wei, X., Pu, X., Yang, S., Meng, X., Chen, X., Zhang, Z., Sheng, X., Xiang, D., & Zhang, Y. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.09.26 · Cited by 6
“The prognosis for patients with APL has improved in recent decades following the application of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA)-based therapies (2,3).”
BackgroundInfluentialClinical significance of mitochondrial DNA content in acute promyelocytic leukaemia
Pereira‐Martins, D. A., Coelho‐Silva, J. L., Weinhäuser, I., Franca-Neto, P. L., Silveira, D. R., Rojas, C. A. O., Moreira‐Aguiar, A., Lima, M. M., Koury, L. C. A., de Melo, R. A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18510 · Cited by 6
Self-citationAbla, O., & Kwaan, H. C. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_8 · Cited by 7
Hajj, H. E., Ali, J., Ghantous, A., Hodroj, D., Daher, A., Zibara, K., Journo, C., Otrock, Z. K., Zaatari, G. S., Mahieux, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079474 · Cited by 6
Kolhe, R. B., Mangaonkar, A. A., MANSOUR, J., Clemmons, A. B., Shaw, J., Dupont, B., Walczak, L., Mondal, A. K., Rojiani, A. M., Jillella, A., et al. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12326 · Cited by 6
Kaoukabi, A., Belachemi, L., Lahcini, M., Viaud‐Massuard, M., & Croix, C. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3478 · Cited by 6
Addressing the room for improvement in management of acute promyelocytic leukemia
Nørgaard, J. M., Friis, L. S., Kristensen, J. S., Severinsen, M. T., Mølle, I., Marcher, C. W., Møller, P., Schöllkopf, C., Nielsen, O. J., Preiss, B., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13229 · Cited by 6
“Rare variants of APL, that is, cases of acute leukemia with complex rearrangements involving PML‐RARA, and cases with t(11;17)(q13;q21), t(11;17)(q23;q21), or t(5;17)(q35;q21) were excluded.”
BackgroundLou, Y., Tong, H., Yu, W., Wei, J., Xu, W., Mao, L., & Jin, J. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106168 · Cited by 6
Chien, N., Varghese, C., Green, T. N., Chan, G. T. C., Theakston, E., Eaddy, N., Doocey, R. T., Berkahn, L., Hawkins, T. E., Browett, P., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106358 · Cited by 6
Hazenberg, C. L. E., Diepstra, A., Santing, M., Huls, G. A., & Ammatuna, E. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04720-8 · Cited by 6
“The introduction of all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) as treatment for low-intermediate-risk APL has dramatically improved outcomes and reduced toxicity [1].”
BackgroundKruse, M., Wildner, R., Barnes, G., Martin, M., Mueller, U. W., Lo‐Coco, F., & Pathak, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134587 · Cited by 6
“Model calculated survival curves overlaid with observed clinical trial data [19].”
BackgroundMethodResultInfluentialSelf-citationBreccia, M., Molica, M., Efficace, F., Minotti, C., Latagliata, R., Foà, R., & Lo‐Coco, F. (2014) · British Journal of Haematology · doi:10.1111/bjh.12995 · Cited by 6
Self-citationConsidering autophagy, β-Catenin and E-Cadherin as innovative therapy aspects in AML
Kuhn, K. D., & Römer, W. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.314 · Cited by 6
Dillon, R. J., & Grimwade, D. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.868458 · Cited by 6
Gill, H., Kwong, Y., & Ravandi, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.831308 · Cited by 6
“In addition, multi-centre clinical trials in patients treated with ATRA, arsenic trioxide and anthracyclines reported a relatively low incidence of early deaths of 3-10% (1, 2).”
BackgroundThe genetic landscape of acute myeloid leukaemia in the South African public sector
Hodkinson, K. E., Willem, P., Moodley, M., Engelbrecht, D., Patel, P., Wiggill, T. M., Ketseoglou, I., van Zijl, H., Vaughan, J., Chapanduka, Z. C., et al. (2024) · South African Journal of Oncology · doi:10.4102/sajo.v8i0.309 · Cited by 5
Association of retinoids, retinoic acid receptors and epigenetics in breast cancer
Szymański, Ł., Schenk, T., Ławiński, M., Brioli, A., & Zelent, A. (2026) · Oncogene · doi:10.1038/s41388-026-03699-8 · Cited by 5
“In acute promyelocytic leukemia, pharmacologic doses of ATRA target oncogenic RAR α fusion proteins and, in combination with arsenic trioxide or chemotherapy, overcome a differentiation block and achieve high cure rates [11].”
Tang, Y., Lv, D., & Hu, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117829 · Cited by 6
The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia
Fabiani, E., Falconi, G., Noguera, N. I., Saulle, E., Cicconi, L., Divona, M., Banella, C., Picardi, A., Cerio, A. M., Boe, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21101 · Cited by 5
Self-citationMyelodysplastic syndromes and acute myeloid leukemias in the elderly
Mueller, B. U., Seipel, K., & Pabst, T. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.026 · Cited by 6
Wen, J., Xu, F., Zhou, Q., Hu, H., Liu, Y., Su, J., Zhang, Y., Qu, W., & Shi, L. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2274 · Cited by 5
“Based on numerous clin‐ ical trials (1,2), the National Comprehensive Cancer Network (NCCN) guideline recommends ATRA combined with ATO as the standard induction treatment for de novo APL with low risk [white blood cell (WBC) count <10x109/l (3).”
BackgroundTedjaseputra, A., Russell, N. H., & Dillon, R. J. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.009 · Cited by 7
Versluis, J., Cornelissen, J. J., Craddock, C., Sanz, M. Á., & Nagler, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-44080-9_70 · Cited by 7
EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness
Cocchi, S., Greco, V., Sidarovich, V., Vigna, J., Broso, F., Corallo, D., Zasso, J., Re, A., Rosatti, E. F., Longhi, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094795 · Cited by 6
Xie, S., Liu, H., Zhu, S., Chen, Z., Wang, R., Zhang, W., Xian, H., Xiang, R., Xia, X., Sun, Y., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00818-z · Cited by 7
Xu, L., Xu, Y., Wang, G., Tu, X., Xu, J., Zheng, H., Wang, D., Su, Y., Zhang, X.-K., & Zeng, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116779 · Cited by 5
MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia
Kegyes, D., Thiagarajan, P. S., & Ghiaur, G. (2024) · Cancers · doi:10.3390/cancers16183208 · Cited by 5
“These trials showed the clear superiority of ATRA/ATO in achieving CR, as well as in preventing relapse and, thus, eliminating MRD [62].”
BackgroundMendoza, S. E. S., Wagatsuma, V. M. D. D., do Nascimento, M. C., Lima, K., Machado‐Neto, J. A., Djavaheri‐Mergny, M., & Rego, E. M. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06089-w · Cited by 5
“The all-trans retinoic acid (ATRA) is a vitamin A derivative that is known to cause deep and prolonged molecular remissions when used in combination with chemotherapy or with arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) patients [23, 24].”
Minami, M., Sakoda, T., Kawano, G., Kochi, Y., Sasaki, K., Sugio, T., Jinnouchi, F., Miyawaki, K., Kunisaki, Y., Kato, K., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02530-9 · Cited by 6
Ravandi, F., Rangaraju, S., Kantarjian, H. M., Garcia‐Manero, G., Yilmaz, M. E., Baker, K., Hall, T. G., Grabenstein, J., Roy, P., Zamboni, B. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015453 · Cited by 5
Shukla, N. N., Walsh, M. F., & Walter, R. B. (2022) · doi:10.1182/ashsap8.chapter19 · Cited by 5
Zhang, D., Li, Y., Liu, T., Liu, X., & Zhang, J. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06495-8 · Cited by 5
“Our findings align with Lo-Coco et al. [10] and Burnett et al. [ 11], demonstrating that chemotherapy intensification during induction in low-risk APL primarily increases toxicity without sur - vival benefit.”
Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene
Asou, N. (2017) · Springer eBooks · doi:10.1007/978-981-10-3332-2_11 · Cited by 5
Acute promyelocytic leukemia presenting with features of metastatic osseous disease
Winters, C., Chen, A. I., Moore, S. R., Traer, E. A., & Dunlap, J. B. (2018) · Leukemia Research Reports · doi:10.1016/j.lrr.2018.02.003 · Cited by 5
“Arsenic trioxide (ATO) binds and degrades the PMLRARα fusion protein and works synergistically with ATRA; cure rates with ATRA+ATO now exceed 90% [2].”
BackgroundNauffal, M., Werner, L. L., Ni, J., Stone, R. M., DeAngelo, D. J., & McDonnell, A. (2019) · Leukemia Research Reports · doi:10.1016/j.lrr.2019.100189 · Cited by 5
“observed similar rates of DS between the groups who received ATRA plus arsenic and those who received ATRA plus chemotherapy [21].”
BackgroundRashid, A., Wang, R. Y., Zhang, L. N., Yue, J., Yang, M., & Yen, A. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111989 · Cited by 5
Barsoum, B., Henneman, A., Ahmad, S., & Ghiuzeli, C. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1837797 · Cited by 5
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging
Huang, S., Chen, K., Leung, J., Guagliardo, P. R., Chen, W., Song, W., Clode, P. L., Xu, J., Young, S. G., & Jiang, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02770 · Cited by 5
Masetti, R., Muratore, E., Leardini, D., Baccelli, F., Pession, A., Prete, A., & Locatelli, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135350 · Cited by 6
“and a platelet count of no more than 40×10(9)/L liter at presentation (11).”
BackgroundResultInfluentialArsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse
Li, J., Xiao, S., Shi, F., Song, H., Wu, J., Zheng, D., Chen, X., Tan, K., & Lu, M. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06281-2 · Cited by 6
“In addition, the cases without the age of diagnosis and the age of the cases at the time of follow-up were removed for further analysis.”
Sobas, M., Knopińska‐Posłuszny, W., Piątkowska‐Jakubas, B., García‐Álvarez, F., Amutio, M. E., Caballero, M., Martínez‐Cuadrón, D., Aguiar, E. V., Gonzalez-Campos, J. A., Garrido, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05582-y · Cited by 5
Tian, J., Song, Y., Zhang, G.-C., Wang, S., Chu, X.-X., Chai, Y., Wang, C., He, A., Zhang, F., Shen, X., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05700-x · Cited by 5
“It has been reported that a small prolongation of the QTc interval occurred in patients who received arsenic trioxide, however, to a lesser extent in patients who received RIF, which is consistent with previous reports (Lo-Coco et al. 2013; Zhu et al. 2018).”
ResultKul, A. N., & Kurt, B. O. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01349-5 · Cited by 5
Boscaro, E. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.063 · Cited by 5
Tian, Y., Liu, Y., He, P., Liu, F., Zhou, N.-C., Cheng, X., Shi, L., Zhu, H., Zhao, J., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083184 · Cited by 5
“All trans retinoic acid (ATRA) in combination with anthracycline-based chemotherapy is the standard treatment modality for APL and is able to induce complete remission (CR) in most of the patients with APL through in vivo differentiation of APL blasts, resulting in cure rates exceeding 80% [6,7].”
BackgroundMoosig, F., Reinhold‐Keller, E., Holl‐Ulrich, K., Feller, A. C., Bley, T. A., Holle, J. U., Zwerina, J., Lamprecht, P., Dalhoff, K., Venhoff, N., et al. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-0988-6 · Cited by 7
Yim, C. Y., Mao, P., & Spinella, M. J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9562-2 · Cited by 7
“without DNA-damaging chemotherapy (73).”
Tamibarotene for the treatment of acute promyelocytic leukemia
Takeshita, A., Shinagawa, K., Adachi, M., Ono, T., Kiguchi, T., & Naoe, T. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.943733 · Cited by 5
“Recent studies in combination therapy of ATRA and ATO suggest an excellent clinical outcome for APL [42].”
BackgroundAre adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
Ravandi, F. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.10.005 · Cited by 5
Conflicting Signals for Cancer Treatment
Sujobert, P., & Trautmann, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1393 · Cited by 6
Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis
Ferreyro, B. L., Munshi, L., Detsky, M. E., Minden, M. D., Cheung, A., Burry, L. D., & Lee, C. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.08.004 · Cited by 5
VITAMIN A, RETINOIC ACID AND TAMIBAROTENE, A FRONT TOWARD ITS ADVANCES: A REVIEW
Zhu, G., & Al-Kaf, A. G. (2019) · Universal Journal of Pharmaceutical Research · doi:10.22270/ujpr.v3i6.215 · Cited by 7
Teran, V. A., Wilson, B. B., & Guffey, D. J. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.5258 · Cited by 5
Salamero, O., Martínez‐Cuadrón, D., Sobas, M., Benavente, C., Vives, S., de la Serna, J., Pérez‐Encinas, M., Escoda, L., Gil, C., Brunet, S., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1607327 · Cited by 5
Closing the loop on cohesin in hematopoiesis
Rao, S. (2019) · Blood · doi:10.1182/blood.2019003279 · Cited by 5
Ferla, V., Sciumé, M., Gianelli, U., Baldini, L., & Fracchiolla, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00007 · Cited by 6
“APL: acute promyelocytic leukemia ADR: adverse drug reaction ATO: arsenic trioxide ATRA: all-trans retinoic acid CR: complete remission rate CRP: C-reactive protein CT: computed tomography D-D: D-dimer DIC: disseminated intravascular coagulation Hb: hemoglobin LDH: lactic dehydrogenase PB: peripheral blasts PML: promy…”
BackgroundInfluentialTrisenox Disrupts MDM2-DAXX-HAUSP Complex and Induces Apoptosis in a Mouse Model of Acute Leukemia
Kumar, S., & Tchounwou, P. B. (2020) · Journal of Cancer · doi:10.7150/jca.39996 · Cited by 5
[Analysis of early death factors and prognosis of acute promyelocytic leukemia].
Wu, Y., Wu, D., Chen, S. N., Qiu, H., Han, Y., Li, C. X., Ma, X., Sun, A., Tang, X., & Hu, X. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.12.010 · Cited by 5
Silva-Carvalho, A. É., de Oliveira, N. N., Machado, J. V. L., Moreira, D. C., Brand, G. D., Leite, J. R. S. A., Plácido, A., Eaton, P. J., & Saldanha‐Araújo, F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071864 · Cited by 5
Angka, L., & Spagnuolo, P. A. (2015) · Current Opinion in Food Science · doi:10.1016/j.cofs.2015.03.004 · Cited by 7
Efficacy of arsenic trioxide drug-eluting stents in the treatment of coronary heart disease
Zhang, S., Zhang, Y., Li, S., & Li, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4106 · Cited by 5
Aberrant phenotypes in acute myeloid leukemia in India
Aparna, S. K., & Sharmila, M. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20181069 · Cited by 5
Xu, F., Yin, C., Wang, C., Ding, B., Zhong, Q., Jiang, X., Jiang, L., Wang, Z., & Meng, F. (2018) · Biomedical Reports · doi:10.3892/br.2018.1120 · Cited by 5
Nguyen, R., & Dyer, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00003-5 · Cited by 6
Bolis, M., Terao, M., Pattini, L., Garattini, E., & Fratelli, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0241-5 · Cited by 5
Bankar, A., Korula, A., Kulkarni, U. P., Devasia, A. J., Fouzia, N. A., Lionel, S. A., Abraham, A., Balasubramanian, P., Arthur, N. B. J., Nair, S. C., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16343 · Cited by 5
Wolanin, S., McCall, R. K., Pettenati, M. J., Beaty, M. W., Insuasti‐Beltran, G., Powell, B. L., & O’Neill, S. S. (2020) · Case Reports in Hematology · doi:10.1155/2020/8830595 · Cited by 7
Role of cofilin‑1 in arsenic trioxide‑induced apoptosis of NB4‑R1 cells
Zhu, H., Zheng, X., Feng, H., Wang, W., Wang, X., Li, M., Wang, H., Zhao, J., & He, P. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11570 · Cited by 5
“and arsenic trioxide (as2o3) treatment is recommended as the first‐line treatment for low‐risk APL worldwide (5), with a complete remission rate of 94‐100%, a 2‐year overall survival rate of 97% and a 4‐year survival rate of 93% (6,7).”
BackgroundLi, S., Lu, Y., Liu, H., Gang, E. J., Le, J., Qian, S.-Y., Tang, S., Si, T., & Pei, R. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1856832 · Cited by 5
“reported 2-year EFS of 97% in the ATRAATO arm compared to 86% in the ATRA/Chemo arm [6].”
MethodExtemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia
Przybylski, D. J., Jared, J. R., & Fallon, M. J. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221990091 · Cited by 5
Selection and identification of an ssDNA aptamer to NB4 cell
Zhang, X., Wang, W., & Chen, X. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23718 · Cited by 5
Glass, J. L., Derkach, A., Hilden, P. D., King, A. C., Seo, S. K., Ahr, K. F., Kishtagari, A., Levine, R. L., Tallman, M. S., & Douer, D. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106569 · Cited by 5
Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico
Zapata-Canto, N. P., Aguilar, M., Arana-Luna, L. L., Montano, E., Ramos-Penafiel, C., la Pena, J. A. D., Álvarez-Vera, J. L., Espitia-Rios, E., Pérez-Zúñiga, J. M., Hernández-Ruiz, E., et al. (2021) · Journal of Hematology · doi:10.14740/jh773 · Cited by 5
“APL0406 [33, 34] Idarubicin and ATRA-based induction and consolidation; maintenance for 2 years 137 93% at 50 months 80% at 50 months”
BackgroundMethodResultInfluentialTroitskaya, V. V., Parovichnikova, E. N., Semenova, A. A., Таймуразовна, Ф. З., Соколов, А. Н., Galstyan, G. M., Спирин, М. В., Грибанова, Е. О., Sysoeva, E., Николаевна, Д. В., et al. (2021) · Гематология и трансфузиология · doi:10.35754/0234-5730-2021-66-2-168-191 · Cited by 5
MacDougall, K. N., Chukkalore, D., Rehan, M., Kashi, M., & Bershadskiy, A. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1973657 · Cited by 5
“The patient completed induction chemotherapy with ATRA and arsenic trioxide (ATO) according to the Lo-Coco protocol[8].”
MethodPostremission Therapy in Acute Promyelocytic Leukemia: Room for Improvement?
Lancet, J. E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5549 · Cited by 5
“In a recent landmark randomized study, the combination of ATRA plus ATO demonstrated equal (noninferior) efficacy and lower toxicity than ATRA plus chemotherapy in non–high-risk APL, potentially changing the therapeutic paradigm for APL.(28) Nevertheless, the role of ATO as a riskadaptive strategy following remission…”
BackgroundAdvances in biology and therapy
Rajkumar, S. V., & Moreau, P. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.172 · Cited by 5
Development of treatment and clinical results in childhood AML in Austria (1993–2013)
Boztug, H., Mühlegger, N., Glogova, E., Mann, G., Urban, C. E., Meister, B., Schmitt, K., Jones, N., Attarbaschi, A., Haas, O. A., et al. (2014) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0135-y · Cited by 5
“Other types of targeted treatment, e.g., using tyrosinekinase inhibitors tackling aberrant signaling (e.g., by FLT3-ITD), may be options for increasing survival rates in selected cohorts without further increasing classical chemotherapy toxicity [32] .”
BackgroundUdupa, K., Thomas, J., Udupa, C. B. K., Binu, V. S. N., & Sharan, P. (2016) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-016-0668-9 · Cited by 5
“[12] where ATRA and ATO has emerged as new standard of care in the treatment of low and intermediate risk APML compared to ATRA and chemotherapy in terms of friendly toxicity profile, better event free survival and overall survival.”
BackgroundPML-RARA mutations confer varying arsenic trioxide resistance
Bai, D., & Zheng, X. (2016) · Protein & Cell · doi:10.1007/s13238-016-0356-4 · Cited by 5
“Arsenic trioxide (AS2O3), an ancient traditional Chinese medicine, has recently been adopted as the first-line treatment for APL patients by the National Comprehensive Cancer Network (Wang and Chen, 2008; Zhu and Huang, 2014), which greatly improved the 5-year overall survival of APL patients (Li et al., 2002; Zhou et…”
BackgroundArsenic Trioxide: Clinical Pharmacology and Therapeutic Results
Emi, N. (2017) · Springer eBooks · doi:10.1007/978-981-10-3332-2_13 · Cited by 5
Levis, M. J. (2021) · Haematologica · doi:10.3324/haematol.2021.278984 · Cited by 5
“Department of Oncology, Johns Hopkins University, Baltimore, MD, USA E-mail: MARK LEVIS - levisma@jhmi.edu doi:10.3324/haematol.2021.278984 In this issue of Haematologica, Kayser and colleagues report the results of an analysis of outcomes from the National Acute Promyelocytic Leukemia (APL) Observational study (NAPOL…”
InfluentialBoush, M., Kiaei, A. A., & Mahboubi, H. (2023) · medRxiv · doi:10.1101/2023.08.17.23294228 · Cited by 5
“As a result, APL has emerged as the most easily treatable form of acute myeloid leukemia [101], [102], [115], [116].”
BackgroundHussain, H., Zaidi, S. M. F., Hasan, S. M., Jahan, A. S., Rangwala, B. S., Rangwala, H. S., Ali, M., & Farah, A. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001888 · Cited by 5
Recent progress in AML with recurrent genetic abnormalities
Ishikawa, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03848-3 · Cited by 7
Chang, J., Yan, S., Geng, Z., & Wang, Z. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109677 · Cited by 5
Wang, Y., Luo, Y., Leng, Y., Yang, M., Liang, T., & Niu, T. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074196 · Cited by 4
Cingelová, S., Mikuskova, E., Demitrovičová, Ĺ., Mikudova, V., Slobodova, A., Spanikova, J., Vasickova, R., Urban, D., Drgoňa, Ľ., & Oravcová, I. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107567 · Cited by 4
Yanada, M. (2024) · British Journal of Haematology · doi:10.1111/bjh.19763 · Cited by 6
Proteogenomic profiling of acute myeloid leukemia to identify therapeutic targets
Murray, H. C., Sillar, J. R., Chambers, M., & Verrills, N. M. (2024) · Expert Review of Proteomics · doi:10.1080/14789450.2024.2431272 · Cited by 4
Ma, J., Sun, S., Xie, Y., Zhou, S., Wu, M., Zuo, X., Xie, M., & Wang, X. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01228-6 · Cited by 4
Targeted mitochondrial metabolism for anti-tumor therapy
Yan, C., Li, X., Pei, W., Zhang, X., Wang, H., Chen, Z., Lin, F., & Lu, G. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102073 · Cited by 4
Cai, Q., Ye, B., Zheng, W., Zhang, S., Zhang, J., Shen, Y., Yao, D., Zhang, H., Huang, Z., Hu, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15034-7 · Cited by 4
Predictors of Early Death in Acute Promyelocytic Leukemia
Infante, J. B. (2025) · Medical Sciences · doi:10.3390/medsci13040300 · Cited by 6
Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope
Olesinski, E. A., & Bhatt, S. (2025) · Biomedicines · doi:10.3390/biomedicines13123007 · Cited by 6
Dhakal, P., Lyden, E. R., Joshi, U., Pyakuryal, A., Loh, K. P., Klepin, H. D., & Bhatt, V. R. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2165394 · Cited by 4
“Practice-changing clinical trials do not report data on comorbidities [8,9].”
BackgroundGonçalves, A., Rocha, F. A., & Estevinho, B. N. (2023) · Pharmaceuticals · doi:10.3390/ph16020180 · Cited by 4
“In another study, the Italian cooperative group GIMEMA worked in collaboration with the German AMLSG and SAL cooperative groups to perform randomized studies to compare the combination of all-trans RA and chemotherapy against the chemotherapy-free approach [47].”
Akman, B. T., Arica, D. A., Koca, E., & Karakuş, S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231216050 · Cited by 4
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.